Smallpox vaccine Jynneos Ph III data peer reviewed by NEJM

14 November 2019

Bavarian Nordic (OMX: BAVA) today announced that results from the pivotal Phase III efficacy trial of its smallpox vaccine, MVA-BN, have been peer-reviewed and published in prestigious New England Journal of Medicine (NEJM).

The Phase III trial was the final clinical study to support the registration of the vaccine, which was approved in September this year by the US Food and Drug Administration, along with the granting of a priority voucher from the FDA. The vaccine, marketed as Jynneos, is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older.

“We are very proud that our research has been acknowledged by The New England Journal of Medicine. The fact that the study results have been published by such an esteemed journal underpins the importance of the data to the medical community,” said Paul Chaplin, president and chief executive of Bavarian Nordic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK